HIV RNA suppression rates after 24 weeks of treatment with etravirine, darunavir/ritonavir and raltegravir in the etravirine early access programme

E. Florence, S. De Wit, A. Castagna, E. Ribera, A. Hill, H. Vanaken, Y. Van Delft, S. Marks

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)224-225
Number of pages2
JournalInternational Journal of STD and AIDS
Volume21
Issue number3
DOIs
Publication statusPublished - Mar 2010

ASJC Scopus subject areas

  • Dermatology
  • Public Health, Environmental and Occupational Health
  • Pharmacology (medical)
  • Infectious Diseases

Cite this